Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease

BACKGROUND: Prostate-specific antigen (PSA) screening for prostate cancer results in a large number of unnecessary prostate biopsies. There is a need for specific molecular markers that can be used in combination with PSA to improve the specificity of PSA screening. We examined GADD45a methylation i...

Descripción completa

Detalles Bibliográficos
Autores principales: Reis, I M, Ramachandran, K, Speer, C, Gordian, E, Singal, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522641/
https://www.ncbi.nlm.nih.gov/pubmed/26171936
http://dx.doi.org/10.1038/bjc.2015.240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522641/
https://www.ncbi.nlm.nih.gov/pubmed/26171936
http://dx.doi.org/10.1038/bjc.2015.240

Ejemplares similares